1.0Okuvisionhttps://okuvision.de/en/Melanie Brollhttps://okuvision.de/en/news/author/melanie-broll/Press Release - CE Marking for OkuStim® 2rich600338<blockquote class="wp-embedded-content" data-secret="on1PS2gRzp"><a href="https://okuvision.de/en/news/pm-os2/">Press Release – CE Marking for OkuStim® 2</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://okuvision.de/en/news/pm-os2/embed/#?secret=on1PS2gRzp" width="600" height="338" title="“Press Release – CE Marking for OkuStim® 2” — Okuvision" data-secret="on1PS2gRzp" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script type="text/javascript">
/* <![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://okuvision.de/wp-includes/js/wp-embed.min.js
/* ]]> */
</script>
https://okuvision.de/wp-content/uploads/2025/12/OS2_02.webp1350899With OkuStim® 2, Okuvision is launching an innovative therapy platform that allows patients to perform Retinitis pigmentosa treatment at home. The neurostimulator for transcorneal electrical stimulation, featuring current CE marking in accordance with the EU Medical Device Regulation (MDR), was honored with the German Design Award 2026 (Gold) for its ergonomic design.